[Optic neuropathies].
Chevaleraud
J P
JP
Hamard
H
H
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects; D002491:Central Nervous System Agents / Q000009:adverse effects; D007464:Clioquinol / Q000009:adverse effects; D006801:Humans; D009896:Optic Atrophy / Q000139:chemically induced; D009901:Optic Nerve Diseases / Q000139:chemically induced* / Q000175:diagnosis; D009902:Optic Neuritis / Q000139:chemically induced; D010211:Papilledema / Q000139:chemically induced; D010480:Perhexiline / Q000009:adverse effects / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D000995:Antitubercular Agents; D002491:Central Nervous System Agents; D007464:Clioquinol; C023470:perhexiline maleate; D010480:Perhexiline
Neuropathies optiques.